JPH11500738A - アルコール嗜癖の治療のための薬剤の製造におけるフォルスコリンまたはそれを含んでいる抽出物の使用 - Google Patents
アルコール嗜癖の治療のための薬剤の製造におけるフォルスコリンまたはそれを含んでいる抽出物の使用Info
- Publication number
- JPH11500738A JPH11500738A JP8534525A JP53452596A JPH11500738A JP H11500738 A JPH11500738 A JP H11500738A JP 8534525 A JP8534525 A JP 8534525A JP 53452596 A JP53452596 A JP 53452596A JP H11500738 A JPH11500738 A JP H11500738A
- Authority
- JP
- Japan
- Prior art keywords
- alcohol
- forskolin
- treatment
- medicament
- alcohol addiction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 title claims abstract description 28
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 14
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 title claims abstract description 14
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 title claims abstract description 5
- 239000003814 drug Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title description 2
- 229940079593 drug Drugs 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 201000007930 alcohol dependence Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 229940084657 Benzodiazepine receptor inverse agonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001646851 Coleus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. アルコール嗜癖の治療用薬剤の調製のためのフォルスコリンの使用。 2. アルコール嗜癖の治療用薬剤の調製のためのフォルスコリンを含んでいる 抽出物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI951023A IT1275436B (it) | 1995-05-19 | 1995-05-19 | Uso della forskolina e di estratti che la contengono per il trattamento della alcol-dipendenza |
IT95A001023 | 1995-05-19 | ||
PCT/EP1996/001952 WO1996036332A1 (en) | 1995-05-19 | 1996-05-09 | Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11500738A true JPH11500738A (ja) | 1999-01-19 |
JP3001641B2 JP3001641B2 (ja) | 2000-01-24 |
Family
ID=11371634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8534525A Expired - Fee Related JP3001641B2 (ja) | 1995-05-19 | 1996-05-09 | アルコール嗜癖の治療のための薬剤の製造におけるフォルスコリンまたはそれを含んでいる抽出物の使用 |
Country Status (18)
Country | Link |
---|---|
US (1) | US5902823A (ja) |
EP (1) | EP0825859B1 (ja) |
JP (1) | JP3001641B2 (ja) |
KR (1) | KR100423486B1 (ja) |
CN (1) | CN1099286C (ja) |
AT (1) | ATE215368T1 (ja) |
AU (1) | AU697449B2 (ja) |
CA (1) | CA2221592C (ja) |
DE (1) | DE69620394T2 (ja) |
DK (1) | DK0825859T3 (ja) |
ES (1) | ES2175099T3 (ja) |
HK (1) | HK1005651A1 (ja) |
HU (1) | HU223474B1 (ja) |
IT (1) | IT1275436B (ja) |
NO (1) | NO316054B1 (ja) |
PT (1) | PT825859E (ja) |
RU (1) | RU2183455C2 (ja) |
WO (1) | WO1996036332A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1001797B9 (en) | 1997-07-30 | 2005-11-23 | INDENA S.p.A. | Soya extract, process for its preparation and pharmaceutical composition |
EP1645272A3 (en) * | 1998-05-12 | 2008-11-05 | The Endowment For Research In Human Biology, Inc. | Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse |
US20060122261A1 (en) * | 2003-11-20 | 2006-06-08 | Muhammed Majeed | [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications] |
US20100144885A1 (en) * | 2006-09-29 | 2010-06-10 | The Board Of Trustees Of The University Of Illinois | Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4120975A (en) * | 1976-08-26 | 1978-10-17 | Fisons Limited | Method of psychiatric conditions |
US4782082A (en) * | 1982-12-27 | 1988-11-01 | Schering Corporation | Method for treating allergic reactions with Forskolin |
IL89530A0 (en) * | 1989-03-08 | 1989-09-10 | Jeffrey J Feigenbaum | Compositions containing forskolin |
US5366990A (en) * | 1991-11-14 | 1994-11-22 | Reid Larry D | Method for treating alcohol abuse and alcoholism |
-
1995
- 1995-05-19 IT ITMI951023A patent/IT1275436B/it active IP Right Grant
-
1996
- 1996-05-09 AU AU58163/96A patent/AU697449B2/en not_active Ceased
- 1996-05-09 KR KR1019970708221A patent/KR100423486B1/ko not_active IP Right Cessation
- 1996-05-09 AT AT96919731T patent/ATE215368T1/de not_active IP Right Cessation
- 1996-05-09 RU RU97120756/14A patent/RU2183455C2/ru active
- 1996-05-09 US US08/952,472 patent/US5902823A/en not_active Expired - Fee Related
- 1996-05-09 HU HU9801236A patent/HU223474B1/hu not_active IP Right Cessation
- 1996-05-09 DE DE69620394T patent/DE69620394T2/de not_active Expired - Fee Related
- 1996-05-09 PT PT96919731T patent/PT825859E/pt unknown
- 1996-05-09 EP EP96919731A patent/EP0825859B1/en not_active Expired - Lifetime
- 1996-05-09 CA CA002221592A patent/CA2221592C/en not_active Expired - Fee Related
- 1996-05-09 CN CN96194036A patent/CN1099286C/zh not_active Expired - Fee Related
- 1996-05-09 ES ES96919731T patent/ES2175099T3/es not_active Expired - Lifetime
- 1996-05-09 WO PCT/EP1996/001952 patent/WO1996036332A1/en active Search and Examination
- 1996-05-09 DK DK96919731T patent/DK0825859T3/da active
- 1996-05-09 JP JP8534525A patent/JP3001641B2/ja not_active Expired - Fee Related
-
1997
- 1997-11-10 NO NO19975155A patent/NO316054B1/no not_active IP Right Cessation
-
1998
- 1998-06-03 HK HK98104794A patent/HK1005651A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ITMI951023A0 (it) | 1995-05-19 |
AU697449B2 (en) | 1998-10-08 |
JP3001641B2 (ja) | 2000-01-24 |
EP0825859A1 (en) | 1998-03-04 |
ES2175099T3 (es) | 2002-11-16 |
PT825859E (pt) | 2002-08-30 |
CA2221592A1 (en) | 1996-11-21 |
CN1184422A (zh) | 1998-06-10 |
HUP9801236A2 (hu) | 2000-06-28 |
US5902823A (en) | 1999-05-11 |
CA2221592C (en) | 2002-07-09 |
HUP9801236A3 (en) | 2001-09-28 |
HK1005651A1 (en) | 1999-01-22 |
DK0825859T3 (da) | 2002-07-29 |
DE69620394D1 (de) | 2002-05-08 |
AU5816396A (en) | 1996-11-29 |
WO1996036332A1 (en) | 1996-11-21 |
ATE215368T1 (de) | 2002-04-15 |
EP0825859B1 (en) | 2002-04-03 |
DE69620394T2 (de) | 2002-10-02 |
KR19990014876A (ko) | 1999-02-25 |
KR100423486B1 (ko) | 2004-06-05 |
RU2183455C2 (ru) | 2002-06-20 |
ITMI951023A1 (it) | 1996-11-19 |
NO975155D0 (no) | 1997-11-10 |
NO316054B1 (no) | 2003-12-08 |
IT1275436B (it) | 1997-08-07 |
NO975155L (no) | 1997-11-10 |
HU223474B1 (hu) | 2004-07-28 |
CN1099286C (zh) | 2003-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5532244A (en) | Potentiation of drug response | |
US6124337A (en) | Methods and formulations for modulating the human sexual response | |
JP2011079853A (ja) | 男性および女性の性交不能の処置に有用な配合剤 | |
JP4603351B2 (ja) | 男性及び女性のインポテンスの治療において有用な製剤 | |
US20030022910A1 (en) | Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine | |
EP0824356B1 (en) | Pharmaceutical compositions for the treatment of alcohol addiction | |
JPH11500738A (ja) | アルコール嗜癖の治療のための薬剤の製造におけるフォルスコリンまたはそれを含んでいる抽出物の使用 | |
EP1082122A1 (en) | Isoflavonoids for treatment and prevention of migraine headaches | |
CN106831679A (zh) | 新党参炔醇类化合物及其制备方法、应用和其药物组合物 | |
JP2000119187A (ja) | 抑うつ気分の予防または改善用組成物 | |
US20070028930A1 (en) | Active agent and formulations to minimize or alleviate bladder urgency and irritation and/or to enhance sexual function | |
JP7494186B2 (ja) | 下部尿路症状の処置および/または防止のための組成物 | |
EP3206701B1 (de) | Canephron zur behandlung von prostatitis | |
TW202015669A (zh) | 夜間頻尿之預防或改善劑 | |
Tornatore et al. | Reactions to Antidepressants: Tricyclic and Tetracyclic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081112 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081112 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091112 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101112 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |